Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
Tissue Transglutaminase
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "Tissue Transglutaminase" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
ZM39923 hydrochloride is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 hydrochloride also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM.
Cat. No.: HY-113089
CAS No.: 17105-15-6
Synonyms: H-Glu(H-Lys-OH)-OH; γ-Glu-ε-Lys
Target:
Cat. No.: HY-113089A
Purity: 98.55%
Synonyms: H-Glu(H-Lys-OH)-OH TFA; γ-Glu-ε-Lys TFA
Target:
Target:
Research Areas:
MT-4 is a derivative of a tissue transglutaminase (TG2) inhibitor. MT-4 targets the complex of TG2 and fibronectin (FN) (TG2/FN) and inhibits the adhesion of tumor cells to the matrix. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum and increases the sensitivity of OC cells to paclitaxel.
Cat. No.: HY-E70437
CAS No.: 80146-85-6
Synonyms: Tissue-type Transglutaminase; TG2; TGase 2
Target:
Research Areas:
Guinea pig liver transglutaminase (Tissue-type transglutaminase) is an exoenzyme. Enzymes have high catalytic efficiency, high specificity, and mild operating conditions. It can be applied in industries such as pharmaceuticals, industrial production, food manufacturing, and aquaculture .
Cat. No.: HY-102073
CAS No.: 946369-04-6
Target:
Research Areas:
TG53 is a potent inhibitor of tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction. TG53 inhibits formation of a complex with integrin β1 and activation of FAK and c-Src during SKOV3 cell attachment onto FN. TG53 can be used for ovarian cancer research .
Cat. No.: HY-113089AR
Synonyms: H-Glu(H-Lys-OH)-OH TFA (Standard); γ-Glu-ε-Lys TFA (Standard)
Category:
Cat. No.: HY-155643
CAS No.: 3033465-55-0
Target:
Research Areas:
PROTAC TG2 degrader-1 (compound 11) is a von Hippel-Lindau (VHL)-based PROTAC targeting tissue transglutaminase (TG2) with a KD of 68.9 μM. PROTAC TG2 degrader-1 reduces TG2 in ovarian cancer cells in a proteasome-dependent manner .
Cat. No.: HY-12589A
CAS No.: 273727-89-2
Target:
Research Areas:
ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM.
Cat. No.: HY-123933
CAS No.: 330471-93-7
Target:
Research Areas:
TTGM 5826 is a tissue transglutaminase (tTG) inhibitor with an EC50 of 20 μM. TTGM 5826 stabilizes the open conformation of tTG that exhibits protein cross-linking activity, and acts as a competitive inhibitor of tTG-mediated cross-linking activity. TTGM 5826 inhibits the transformed phenotypes of breast cancer cells, brain cancer cells and glioma stem cells. TTGM 5826 can be used in the research of breast cancer, glioblastoma, pancreatic cancer and glioma stem cell-related tumors .
Cat. No.: HY-P71132A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TGM2; Transglutaminase C; Transglutaminase 2; Transglutaminase H; TGC; Transglutaminase-2; Protein-Glutamine Noradrenalinyltransferase TGM2; Heart G Alpha(H); Protein-Glutamine Gamma-Glutamyltransferase 2; HhG Alpha(H); Protein-Glutamine Histaminyltransfe
Species:
Mouse
Source:
HEK293
Cat. No.: HY-167262
CAS No.: 156691-86-0
Target:
Research Areas:
AGN-191659 is an orally active RAR/RXR agonist with EC50 values of 11 nM, 23 nM, and 37 nM for RXRα, RARβ, and RARγ, respectively. AGN-191659 activates RXRα, RARβ and RARγ to induce gene transcription. AGN-191659 induces tissue transglutaminase activity, inhibits ornithine decarboxylase activity induced by tumor promoters, and suppresses chondrogenesis. AGN-191659 reverses basic fibroblast growth factor-induced endothelial cell proliferation. AGN-191659 induces hypertriglyceridemia in rat models. AGN-191659 inhibits total heparin-releasable lipase activity. AGN-191659 can be used in research related to promyelocytic leukemia and hypertriglyceridemia .
Cat. No.: HY-184378
CAS No.: 2922221-22-3
Target:
Research Areas:
MDB5 is a Hedgehog pathway and Smoothened inhibitor that binds to the 7-TM domain of Smo . MDB5 reduces hepatic stellate cell activation, extracellular matrix-related gene expression, collagen deposition, hydroxyproline content and epithelial-mesenchymal transition, and prevents sinusoidal endothelial cell capillarization . MDB5 induces G1 and S phase cell cycle arrest, triggers apoptosis by upregulating Bax and downregulating Bcl-2, and also decreases oxygen consumption rate, glucose uptake, transglutaminase activity and fibronectin matrix assembly . MDB5 reduces the levels of liver injury markers, hepatic triglyceride deposition and hepatic steatosis, restores the tissue structure of the kidney and spleen, and inhibits pancreatic tumor growth without causing body weight loss . MDB5 can be loaded into PEG-PCC-g-DC micelles, achieving high drug loading, sustained release, improved water solubility, enhanced cellular uptake and optimized hepatic distribution, with good tolerance in mice . MDB5 is applicable to research related to alcohol-associated liver disease, liver fibrosis and pancreatic cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
